Anger over cancer drug decision

A life-extending drug hailed as a breakthrough for prostate cancer sufferers is too expensive to be used on the NHS, watchdogs have ruled.

Cabazitaxel, which is marketed as Jevtana, can extend the life of late-stage patients by an average of three months.